Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.
Modern chemotherapy for lymphoma and solid tissue malignancy is most frequently administered in a cyclical fashion on an outpatient basis over many months. During this time patients have a significant risk of developing severe neutropenia due to the myelotoxic effects of the treatment regimens; this increases the risk of potentially life-threatening infection. The risk of grade IV neutropenia (<0.5 x 10(9)/L) ranges from approximately 20% to >70% depending upon the cytotoxic potential of the regimen. The risks of infection associated with severe neutropenia range from approximately 10-20% to >50%. Haematopoietic growth factors have had only minimal impact on these risks and on the natural history of febrile neutropenic events that occur during the course of cancer chemotherapy.
Department of Medicine, University of Manitoba, and the Manitoba Cancer Treatment and Research Foundation, Winnipeg, Canada.
E J
EJ
Bow
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005334:Fever / Q000209:etiology*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D009503:Neutropenia / Q000209:etiology* / Q000276:immunology; D009894:Opportunistic Infections / Q000276:immunology; D012306:Risk
D000970:Antineoplastic Agents